Synchronous and metachronous bilateral breast cancer: A long-term single-institution experience

Medical Oncology

Volumn 29, Issue 1, 2012, Pages 16-24

  Díaz, Robert ^a   Munárriz, Blanca ^a   Santaballa, Ana ^a   Palomar, Laura ^a   Montalar, Joaquín ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Bilateral breast cancer; Estrogen; Hormonal therapy; Mammography; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CANCER RISK; CONTROLLED STUDY; DISEASE FREE INTERVAL; DISEASE SEVERITY; FAMILY HISTORY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; METACHRONOUS BILATERAL BREAST CANCER; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; SYNCHRONOUS BILATERAL BREAST CANCER;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASMS, MULTIPLE PRIMARY; NEOPLASMS, SECOND PRIMARY; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES;

EID: 84864068841     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9785-8     Document Type: Article

References (41)

1. Soerjomataram I, et al. Risks of second primary breast and uro-genital cancer following female breast cancer in the south of The Netherlands, 1972-2001. Eur J Cancer. 2005;41:2331-7. (Pubitemid 41415610)
2. Lu W, et al. The value of surveillance mammography of the contralateral breast in patients with a history of breast cancer. Eur J Cancer. 2009;45:3000-7.
3. Chen Y, Thompson W, Semenciw R, Mao Y. Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev. 1999;8:855-61. (Pubitemid 29508719)
4. Bernstein JL, Lapinski RH, Thakore SS, Doucette J, Thompson WD. The descriptive epidemiology of second primary breast cancer. Epidemiology. 2003;14:552-8. (Pubitemid 40417036)
5. Heron DE, Komarnicky LT, Hyslop T, Schwartz GF, Mansfield CM. Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease. Cancer. 2000;88:2739-50. (Pubitemid 30417934)
6. Healey EA, et al. Contralateral breast cancer: clinical characteristics and impact on prognosis. J Clin Oncol. 1993;11:1545-52. (Pubitemid 23228261)
7. Irvine T, Allen DS, Gillett C, Hamed H, Fentiman IS. Prognosis of synchronous bilateral breast cancer. Br J Surg. 2009;96: 376-80.
8. Bernstein JB, Thompson WD, Risch N, Holford TR. Risk factors predicting the incidence of second primary breast cancer among women diagnosed with a first primary breast cancer. Am J Epidemiol. 1992;136:925-36.
9. Li CI, Malone KE, Porter PL, Daling Jr. Epidemiologic and molecular risk factors for contralateral breast cancer among young women. Br J Cancer. 2003;89:513-8. (Pubitemid 37026436)
10. Malone KE, et al. Family history of young women with invasive breast carcinoma. Cancer. 1996;78:1417-25. (Pubitemid 26317861)
11. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451-67.
12. Early Breast Cancer Trialists' Collaborative Group. Polychemo-therapy for early breast cancer: an overview of the randomised trials. Lancet. 1998;352:930-45.
13. Boice JD Jr, et al. Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med. 1992;326:781-5.
14. Hooning MJ, et al. Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer. J Clin Oncol. 2008;26:5561-8.
15. Khatcheressian JL, et al. American Society of Clinical Oncology. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol. 2006;24:5091-7. (Pubitemid 46631413)
16. Montgomery DA, Krupa K, Cooke TG. Follow-up in breast cancer: does routine clinical examination improve outcome? A systematic review of the literature. Br J Cancer. 2007;97: 1632-41. (Pubitemid 350249350)
17. Lu WL, et al. Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis. Breast Cancer Res Treat. 2009;114:403-12.
18. Field TS, et al. Under utilization of surveillance mammography among older breast cancer survivors. J Gen Intern Med. 2008;23: 158-63.
19. Doubeni CA, et al. Patterns and predictors of mammography utilization among breast cancer survivors. Cancer. 2006;106: 2482-8. (Pubitemid 43787674)
20. Mellink WAM, et al. The contribution of routine follow-up mammography to an early detection of asynchronous contralat-eral breast cancer. Cancer. 1991;67:1844-52.
21. Kollias J, et al. Value of contralateral surveillance mammography for primary breast cancer follow-up. World J Surg. 2000;24: 983-7.
22. Swain SM, et al. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J Natl Cancer Inst. 2004;96:516-23. (Pubitemid 38559575)
23. Stark A, Lu M, Mackowiak P, Linden M. Concordance of the hormone receptors and correlation of HER-2/neu overexpression of the metachronous cancers of contralateral breasts. Breast J. 2005;11:183-7. (Pubitemid 40664061)
24. Arpino G, Weiss HL, Clark GM, Hilsenbeck SG, Osborne CK. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol. 2005;23: 4687-94. (Pubitemid 46224071)
25. Li CI, Malone KE, Weiss NS, Daling Jr. Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer. J Natl Cancer Inst. 2002;93:1008-13.
26. Kaas R, et al. The influence of tamoxifen treatment on the estrogen receptor in metachronous contralateral breast cancer. Br J Cancer. 2002;88:707-10.
27. Bachleitner-Hofmann T, et al. Pattern of hormone receptor status of secondary contralateral breast cancer in patients receiving adjuvant tamoxifen. Clin Cancer Res. 2002;8:3427-32. (Pubitemid 35340717)
28. Kuukasjarvi T, Kononen J, Helin H, Holli K, Isola J. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol. 1996;14: 2584-9. (Pubitemid 26300127)
29. Nelson HD, et al. Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer. Ann Intern Med. 2009;151:703-15.
30. Cuzick J, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361:296-300. (Pubitemid 36126189)
31. Fisher B, et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol. 2001;19:931-42. (Pubitemid 32176267)
32. Baum M, et al. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003;98:1779-81.
33. Goss PE, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793-802. (Pubitemid 37362955)
34. Takahashi H, et al. The impact of bilateral breast cancer on the prognosis of breast cancer: a comparative study with unilateral breast cancer. Breast Cancer. 2005;12:196-202.
35. Jobsen JJ, van der Palen J, Ong F, Meerwaldt JH. Synchronous, bilateral breast cancer: prognostic value and incidence. Breast. 2003;12:83-8. (Pubitemid 36546431)
36. Carmichael AR, Bendall S, Lockerbie L, Prescott R, Bates T. The long-term outcome of synchronous bilateral breast cancer is worse than metachronous or unilateral tumours. Eur J Surg Oncol. 2002;28:388-91.
37. Heaton KM, et al. Feasibility of breast conservation therapy in metachronous or synchronous bilateral breast cancer. Ann Surg Oncol. 1999;6:102-8. (Pubitemid 29077495)
38. Newman LA, et al. A case-control study of unilateral and bilateral breast carcinoma patients. Cancer. 2001;91:1845-53. (Pubitemid 32424110)
39. Robinson E, Rennert G, Rennert HS, Neugut AI. Survival of first and second primary breast cancer. Cancer. 1993;71:172-6. (Pubitemid 23019298)
40. Hartman M, et al. Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J Clin Oncol. 2007;25: 4210-6. (Pubitemid 47548560)
41. Schaapveld M, et al. The impact of adjuvant therapy on contra-lateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat. 2008;110:189-97. (Pubitemid 351793865)